Takeda Pharmaceutical Co. is considering a sale of some emerging-market drugs, as the Japanese drugmaker expands a push to cut debt after its $62 billion takeover of Shire Plc, people familiar with the matter said.
Gilead Sciences Inc. is being roiled by executive departures a year after placing a big bet on the hot world of cancer immunotherapy with its purchase of Kite Pharma.
William Wrigley Jr. II, who helped orchestrate the sale of his family’s business to Mars Inc. in 2008, led a $65 million investment round for Surterra Wellness, a medical cannabis startup in Georgia with licenses to operate in Florida and Texas. The funding brings the total raised so far to $100 million, according to Surterra.
Linde AG shares fell the most in a year after the U.S. antitrust regulator raised an unexpected hurdle to the company’s $42 billion merger with Praxair Inc. that could derail the deal to create the world’s largest industrial gas producer.
Amgen Inc., the maker of cancer treatments and blood boosters to combat anemia, reported first-quarter profit that topped analysts’ estimates and raised its forecast for the year on stronger-than-expected drug sales. The shares rose in late trading.